drugset / Trial / NCT06197438
Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is a single center, phase II study, to evaluate the effectiveness and safety of PD-1 Antibody(Tislelizumab) Plus Irinotecan Combined With POF(paclitaxel plus oxaliplatin plus 5-fluorouracil plus leucovorin) , in the first-line treatment for patients with advanced/metastatic gastric cancer.
Timeline
- Start
- 2024-01-01
- Primary completion
- 2024-04-11
- Completion
- 2025-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 135 mg/m2 | — |
| Subject | Levoleucovorin | Unknown | 200 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 90 mg/m2 | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | — |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | — |